Portfolio - Therapeutics


Alan O'Connell

Heart Metabolics

Heart Metabolics is developing small molecule drugs for cardiovascular diseases. The company has been awarded orphan drug designation by the FDA to treat a rare subset of severe hypertrophic cardiomyopathy (HCM) patients.

Background: HCM is a serious hereditary heart disease. Following positive Phase II clinical results, Heart Metabolics is developing perhexiline to treat the congestive heart failure symptoms of HCM.

Our Involvement: We co-lead the Series A investment with venBio, and we have assisted in the establishment of the company in Ireland. The Irish operation supports the clinical and regulatory activities within the company.

Market Need: HCM is a serious heart condition that affects the heart’s ability to pump normally.  It is the leading cause of sudden cardiac death in young athletes.  The current treatment options for severe HCM are limited, with no FDA approved drugs for these patients.

Status: The company is currently focusing its efforts on completing activities for its planned pivotal Phase III clinical trial.

< back to portfolio